Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Panafina General Information
Panafina holds the intellectual property for RABI-767, a drug candidate in development for patients predicted to advance to severe acute pancreatitis. The program is described as first-of-its-kind and features a new mechanism of action. It is part of Arrivo BioVentures' pipeline, which includes two clinical-stage candidates[1].
Contact Information
Drug Pipeline
Pre-clinical
Key Partnerships
Panafina Funding
No funding data available
To view Panafina's complete valuation and funding history, request access »